Biogen to acquire Apellis Pharmaceuticals stock for $5.6 billion

The $5.6 billion acquisition represents approximately 4% of Biogen's market capitalization, indicating that the financial burden is relatively limited. The cash and stock mixed payment structure, along with existing cash flow (2023 operating income of $1.2B), is manageable, and the debt ratio is expected to remain largely unchanged. Additionally, considering Apellis' revenue base (2023 revenue of $210M) and pipeline value, the expected EPS dilution effect is projected to be in the range of $0.05 to $0.07.

The stock price is showing stability above the support level of $210, and if it breaks through the resistance level of $260, additional upward momentum may be secured. A buy position is recommended at the current level of $235, with consideration for profit realization upon reaching the target price of $260.

Apellis has a next-generation biomarker-based pipeline that includes complement protein inhibitors for the treatment of sarcoidosis (systemic lupus) and antibody therapies for ophthalmic diseases. In particular, the C1q inhibitor, which has entered Phase 3 clinical trials, is expected to synergize with Biogen's existing portfolio for the treatment of neurodegenerative diseases. The integration of the pipeline and the announcement of a joint clinical development roadmap within 12 to 18 months after the acquisition is expected to be a key catalyst.